尿常规白细胞25个不严重，一般情况下，尿常规中白细胞的数量一般都在10个以下，这就是一种简单的判断标准。白细胞25个说明尿常规中有炎症，但是炎症并不严重，在比较严重的情况下，尿常规中白细胞可能在300个以上，所以这种情况不严重。
建议要多喝水，多排尿，一般2-3天症状就会明显改善。建议再次复查尿常规，观察白细胞数量是否会明显减少。同时建议根据尿频、尿急、尿痛的症状，必要时参考尿常规的化验结果，选择好的抗菌素进行治疗。如果症状比较重，可以口服广谱抗菌素。
No-moat Snowflake reported strong third-quarter earnings, with revenue and profitability coming in above guidance. Management now expects fiscal 2025 product revenue growth of 29%, up from the previous guide of 26%. Non-GAAP operating margins are expected to reach 5%, up from the previous guide of 3%, driven by the higher revenue outlook.
While overall results were positive, sending shares up 20% after hours at close to $155 per share, we are revisiting our own expectations as we transfer coverage to a new analyst. We have tempered our long-term revenue growth estimates to reflect increasing competition in the industry and the possibility for growth to decelerate once again over the next several years, which was one of the primary worries throughout this year. While the current quarter's results are a data point suggesting that growth can indeed reaccelerate into the mid-20% range, we are not convinced this type of growth can hold for several more years. As a result, our fair value estimate drops to $129 from $187, and we view shares as moderately overvalued following the after-hours pop.
Third-quarter revenue came in at $942 million, growing 28% year over year and 8% sequentially. Product sales grew 29% year over year due to growing adoption of the firm's AI solutions, new data engineering features, and improving IT budget conditions, offsetting losses in storage revenue from Iceberg's adoption. In addition to strong customer acquisitions, the firm reported a solid net retention rate of 127%. This was the first time in several years that the metric did not decline sequentially, as Snowflake's cross-selling opportunities and customer base continue to mature. Remaining performance obligations were up 55% from the previous year as the firm continues to identify new workloads. We expect contributions from new products and some momentum in AI offerings to drive above-guidance near-term growth, but we remain wary of how long mid-20% growth can last.
